GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Vietnamese Biotech Inc (HSTC:AMV) » Definitions » Debt-to-EBITDA

American Vietnamese Biotech (HSTC:AMV) Debt-to-EBITDA : 0.00 (As of . 20)


View and export this data going back to 2009. Start your Free Trial

What is American Vietnamese Biotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

American Vietnamese Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. American Vietnamese Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. American Vietnamese Biotech's annualized EBITDA for the quarter that ended in . 20 was ₫0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for American Vietnamese Biotech's Debt-to-EBITDA or its related term are showing as below:

HSTC:AMV's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.43
* Ranked among companies with meaningful Debt-to-EBITDA only.

American Vietnamese Biotech Debt-to-EBITDA Historical Data

The historical data trend for American Vietnamese Biotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Vietnamese Biotech Debt-to-EBITDA Chart

American Vietnamese Biotech Annual Data
Trend
Debt-to-EBITDA

American Vietnamese Biotech Quarterly Data
Debt-to-EBITDA

Competitive Comparison of American Vietnamese Biotech's Debt-to-EBITDA

For the Biotechnology subindustry, American Vietnamese Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Vietnamese Biotech's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Vietnamese Biotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where American Vietnamese Biotech's Debt-to-EBITDA falls into.



American Vietnamese Biotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

American Vietnamese Biotech's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

American Vietnamese Biotech's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (. 20) EBITDA data.


American Vietnamese Biotech  (HSTC:AMV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


American Vietnamese Biotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of American Vietnamese Biotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


American Vietnamese Biotech (HSTC:AMV) Business Description

Traded in Other Exchanges
N/A
Address
20 Road 13, Block DC Song Da, Thu Duc Ward, Ho Chi Minh, VNM
American Vietnamese Biotech Incorporation is engaged in trading in pharmaceuticals, purchasing and selling medical equipment, medical testing instruments and chemicals; producing and trading vaccines and medical biological products; real estate business and financial investment.

American Vietnamese Biotech (HSTC:AMV) Headlines

From GuruFocus

Atlis Motor Vehicles to Present Strategies to Build and Expand Charging Infrastructure

By Stock market mentor Stock market mentor 01-19-2023

Atlis Motor Vehicles Reaches 2 Gigawatt-Hours in Customer Demand for Batteries

By Stock market mentor Stock market mentor 01-11-2023